TCGA-EW-A1OY-01A-11R-A144-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 30
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.510
- OXIDATIVE_PHOSPHORYLATION+0.410
- E2F_TARGETS+0.380
- MTORC1_SIGNALING+0.380
- ESTROGEN_RESPONSE_LATE+0.360
- G2M_CHECKPOINT+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.340
- UV_RESPONSE_UP+0.320
- GLYCOLYSIS+0.300
Top 10 suppressed
- NOTCH_SIGNALING-0.400
- HEDGEHOG_SIGNALING-0.350
- ANGIOGENESIS-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- KRAS_SIGNALING_UP-0.300
- UV_RESPONSE_DN-0.290
- ALLOGRAFT_REJECTION-0.280
- TGF_BETA_SIGNALING-0.270
- WNT_BETA_CATENIN_SIGNALING-0.270
- IL6_JAK_STAT3_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454735 | — | E | 0.874 |
| 2 | SRR8518248 | — | E | 0.865 |
| 3 | TCGA-AO-A0JD-01A-11R-A056-07 | — | C | 0.864 |
| 4 | SRR35579804 | — | C | 0.860 |
| 5 | TCGA-A7-A0CJ-01A-21R-A00Z-07 | — | B | 0.853 |
| 6 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.852 |
| 7 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.838 |
| 8 | SRR8518230 | — | E | 0.836 |
| 9 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.834 |
| 10 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |